Transcript Highlights:

• We'd have pharmaceutical transport.
• Whereas, like if you're operating in DFW, that's why if you've seen some of the pharmaceutical deliveries

Keywords: 914, all

Transcript Highlights:

• as you said, this does advance it quite considerably because with, you know, especially with pharmaceuticals
• as you said, this does advance it quite considerably because with, you know, especially with pharmaceuticals

Bills: SB1786

Keywords: artificial intelligence, content verification, provenance data, transparency, digital content, 1182, all

Transcript Highlights:

• struggles with this bill, and one of the biggest ones is this does not provide any incentive for our pharmaceutical
• Pharma charges far too much for pharmaceuticals. Everybody knows that.

Keywords: 908, all

Summary: The Senate reconvened and handled several House messages and conference committee appointments before taking up a series of bills. It appointed conference committees on Senate Bill 2265 and House Bills 1454, 1448, and 1524. The chamber also adopted a Senate amendment to House Bill 1216, delaying its effective date for the copay accumulator prescription drug bill to January 1, 2026, with later renewal timing for non-PERS plans. House Bill 1216 then came up for final passage. Senators debated whether allowing copay accumulator programs to count manufacturer coupons toward deductibles would help patients with expensive drugs or unfairly shift costs to insurers and other policyholders. Supporters said it would help people afford life-saving medications and that the coupon payments go to pharmacies, not insurers; opponents argued it could raise premiums and create perverse incentives for drug pricing. The bill passed 29-18. The Senate also concurred in House amendments to Senate Bill 2160, which changes health insurance benefits under the Uniform Group Insurance Program to move from a grandfathered to a non-grandfathered plan, with supporters emphasizing added benefits and flexibility and opponents warning of higher costs and irreversible changes. That bill passed concurrence 33-14 and final passage 39-8. The Senate next concurred in House amendments to Senate Bill 2339, the wildfire mitigation bill, which requires utility mitigation plans to be updated every two years, incorporate national electric standards, and creates a rebuttable presumption of reasonable care if the plan is followed. The bill then passed final passage 46-1. The chamber also adopted conference committee reports and passed House Bill 1460 on adult foster care and monitoring devices, House Bill 1440 on cigar lounge tobacco use, and Senate Bill 2374 on insurance-related provisions including property insurance arbitration, managed repair programs, and surplus lines issues; SB 2374 also added a study on towing and recovery coverage. The session ended with announcements of upcoming conference committee meetings and adjournment until April 22, 2025.

Transcript Highlights:

• He will be medicated on pharmaceutical drugs for the rest of his life.
• Every pharmaceutical has milligram doses.

Bills: HB441, HB445, HB477, HB441, HB445

Keywords: speech-language pathology, licensure, clinical supervision, educational qualifications, healthcare assistant, hemp-derived cannabinoids, CBD, THC, delta-8, delta-9, delta-10, consumable hemp products, psychoactive cannabinoids, cannabinoid regulation, hemp licensing, ABC Board, Alcoholic Beverage Control Board, retail hemp sales, wholesale hemp distribution, hemp tax

Transcript Highlights:

• Our partnership with Wahoo Bay focuses on ocean sciences, specifically pharmaceuticals and microplastics
• student studied phase-transfer agents, which can be used to prove a variety of chemicals, including pharmaceuticals

Summary: The Senate Committee on Education Postsecondary met to receive an update from Florida developmental research lab schools on articulated health care programs created under the Live Healthy initiative and Senate Bill 76. Chair Calatayud opened the meeting, confirmed a quorum, and heard presentations from P.K. Young/University of Florida, Florida State University Schools, FAMU Developmental Research School, and Florida Atlantic University Laboratory School. Each school described efforts to build K-12-to-postsecondary health care pathways, expand dual enrollment and industry certifications, and share replicable curriculum models with other districts. FSU Schools highlighted its HERO program, including CNA and food manager certifications, dual enrollment growth, reserve seating at colleges, and a paid internship with the Department of Health tied to emergency shelter operations. P.K. Young described its Healthy Lives Blueprint, which combines K-8 wellness experiences, a new high school health and human performance pathway, AP and science course expansion, a planned gymnasium redesign, and partnerships with Santa Fe College and UF. FAMU DRS reported growing dual enrollment, partnerships with FAMU, Tallahassee State, and Lively, and a goal of serving at least 100 students and 40 staff through health career exposure, certifications, and AA/AS pathways. FAU Lab School described a more advanced model that integrates elementary through high school research and health science experiences, including biotechnology, bioengineering, and partnerships with health and research institutions. The school reported 87 peer-reviewed student publications, more than $350,000 in student grants, six patents, and pipelines into FAU’s medical and nursing programs, including a Med Direct pathway and a National Merit Scholar pipeline. Committee members asked about student readiness for nursing programs, dual enrollment, articulation with state colleges, and how the lab school models could be disseminated statewide. The meeting concluded with praise for the programs and a motion by Senator Fine to adjourn, which was adopted without objection.

Transcript Highlights:

• As a woman, I struggle with compound bow.
• </c> compound bows and to be able to um hunt. compound bows and to be able to um hunt.
• Um, I shoot a compound bow.
• Um, I shoot a compound bow.
• Um, I shoot a compound bow.

Keywords: 1187, senate, all

Transcript Highlights:

• YOU WOULD DRIVE THE SPECIES UP AND SEE IF YOU IDENTIFY NEW COMPOUNDS IN THERE AND YOU CAN SEE CHEMICAL
• STRUCTURES HERE, THESE ARE A NUMBER OF THE COMPOUNDS IDENTIFIED THROUGH THIS PROCESS.
• ONE OF THE THINGS THAT IS DONE NOW IS RATHER THAN FIND COMPOUNDS YOU SEQUENCED THE GENES THAT ARE IN
• RATHER THAN TRYING TO FIND THE COMPOUND YOU SEQUENCED THE GENE AND SAY THESE ARE SPECIES THAT CAN DO
• FROM THE OTHER ORGANISMS WE ARE TALKING SOMETHING ON THE ORDER OF OVER 1 MILLION UNIQUE COMPOUNDS.

Keywords: 999, senate, all

Transcript Highlights:

• biosimilar use to bring down costs and inject more competition into a system that brand-name pharmaceutical
• encourage biosimilar use to bring down cost and inject more competition into a system that brand name pharmaceutical
• manufacturers have controlled for ...into a system that brand-name pharmaceutical manufacturers have

Keywords: 987, senate, all

Transcript Highlights:

• encourage biosimilar use... ...to bring down cost and inject more competition into this system that pharmaceutical
• Currently, pharmaceutical companies often offer coupons to privately insured patients in order to provide
• they could lead to uncertainty about a patient's out-of-pocket cost from month to month, since pharmaceutical

Summary: The committee heard several health-related bills, beginning with SB 1124 on lung cancer screening awareness. The author and supporters said the bill would require CDPH signage about lung cancer screening eligibility at tobacco point-of-sale locations to address low awareness and low screening rates. Support came from medical students, physicians, and the California Academy of Family Physicians, while retailers raised concerns about sign size, retailer notification, and implementation. Committee members generally supported the bill and noted the need to work through those concerns. SB 1150 sought to require clearer patient notice when cancer cases are reported to the California Cancer Registry. The author described the bill as a response to inconsistent notification practices and privacy concerns, and the chair and other members shared personal stories about learning they or family members were in the registry without knowing it. Cancer registry and university stakeholders expressed appreciation for amendments but continued to have concerns or wanted more time to review the language. The bill was discussed as a patient-awareness measure rather than a change to reporting requirements. The committee also heard SB 1400 on Alameda Health System governance, SB 1094 on biosimilar substitution and health plan policies, SB 1314 on smoke shop regulation and nitrous oxide restrictions, and SB 1309 on eliminating cost-sharing for medically necessary follow-up after lung cancer screening. SB 1400 and SB 1314 drew support from local officials, labor, and public health advocates, with members emphasizing youth protection and local oversight. SB 1094 passed after extensive debate over pharmacist substitution authority and notification requirements, with a 6-0 vote and opposition from biotechnology and physician groups. SB 1309 also passed after members discussed the cost of follow-up care and the value of early detection, despite opposition from health plans over premium impacts; it received a 7-0 vote and was placed on call.

Transcript Highlights:

• encourage biosimilar use to bring down cost and inject more competition into this system that pharmaceutical
• Currently, pharmaceutical companies often offer coupons to privately insured patients in order to provide
• they could lead to uncertainty about a patient's out-of-pocket cost from month to month, since pharmaceutical

Summary: The committee heard several health-related bills, beginning with SB 1124, which would require the California Department of Public Health to create and post lung cancer screening eligibility signage at tobacco point-of-sale locations. The author and supporters said the bill is intended to raise awareness of a screening that many eligible Californians do not know exists; retailers raised concerns about signage size, distribution, and notice to stores. The bill was presented while the committee lacked quorum, so no vote was taken at that time. Members then heard SB 1150, which would require clearer patient notice when cancer cases are reported to the California Cancer Registry. The author and committee chair emphasized patient awareness and privacy, while registry and university stakeholders said they appreciated the amendments and would continue working on the language. SB 1400 followed, proposing changes to Alameda Health System governance to give Alameda County more flexibility and direct oversight; county and labor supporters said the current structure is too rigid for today’s health care environment, and no opposition was heard. The committee also heard SB 1094, which would expand substitution of biosimilars and generics to lower prescription drug costs. Supporters, including health plans and Sharp Health Care, said the bill would reduce premiums and out-of-pocket costs, while opponents from biotechnology and rheumatology groups raised concerns about pharmacist substitution, patient switching, and therapeutic equivalence. After quorum was established, SB 1094 passed 6-0 and was re-referred to Appropriations. The committee then heard SB 1314, which would create a statewide definition for smoke shops, impose a 600-foot buffer from sensitive sites, and restrict nitrous oxide sales; it drew broad support from local government, pediatric, and law enforcement groups and passed 6-0 on call. SB 1309, which would eliminate cost-sharing for medically appropriate lung cancer screening follow-up care, also passed 7-0 and was re-referred to Appropriations after testimony from clinicians, advocates, and insurers. Finally, SB 1199 was introduced to ban copay accumulators, with the sponsor and author arguing it would ensure patient assistance counts toward out-of-pocket maximums and improve medication access.

Transcript Highlights:

• encourage biosimilar use to bring down cost and inject more competition into this system that pharmaceutical
• Currently, pharmaceutical companies often offer coupons to privately insured patients in order to provide
• they could lead to uncertainty about a patient's out-of-pocket cost from month to month, since pharmaceutical

Keywords: 987, senate, all

Transcript Highlights:

• Pharmaceutical for you, and for your specific DNA to cure whatever ails you.
• If you listen to the example about the benefits of creating a custom pharmaceutical based on your individual
• property through new material science that we can then license out to new battery technology and new pharmaceuticals

Transcript Highlights:

• Our pharmaceuticals tend to go up and down. We do look to generics whenever possible.
• We started a pharmaceutical rebate program last year that's looking to save us $10 million this year,
• And, you know, we leverage the DGS contracting, you know, to get better costs for our pharmaceuticals
• then patient-specific claims, like specialty services, ED services, ambulance, hospital, and pharmaceuticals

Summary: The Senate Budget Subcommittee heard presentations from the Office of the Inspector General (OIG), California Correctional Health Care Services (CCHCS), the California Advancing and Innovating Medi-Cal (CalAIM) program, and the Coleman mental health receivership. The hearing focused on correctional health care, reentry, aging incarcerated populations, and the state’s progress toward compliance in the Plata and Coleman receiverships. Members also discussed the OIG’s intake complaint workload and medical inspection findings, as well as broader questions about staffing, vacancies, and the cost of court oversight. The OIG requested $275,000 General Fund for two permanent positions in its intake processing unit, citing a sharp rise in complaints from 3,200 in 2022 to 7,860 in 2025. OIG officials said complaints are categorized by issue and prison, prioritized by urgency, and generally responded to within 30 days, but they do not track complaint “validity” rates. The medical inspection unit reported that in cycle seven, case review performance was generally adequate while policy compliance was often inadequate; the lowest-scoring areas included emergency services, medication management, and health care environment. Members asked for more detailed reporting on complaint types, priority levels, and systemic issues. CCHCS described rising health care costs driven by an aging prison population, staffing vacancies, and contract medical expenses. Officials said more than 80% of the budget is personal services, and they are using hiring events, social media outreach, and expanded classifications to reduce vacancies. CalAIM officials reported early implementation success in pre-release and reentry services, including 89% Medi-Cal activation at release, 87% assigned managed care plans, 88% reentry care plans, and 59% warm handoffs, with about 169,000 claims submitted and $14.7 million reimbursed. The LAO noted that the Plata medical receivership has increased per-person costs and that the state should continue oversight while seeking ways to reduce vacancies and expand federal reimbursement opportunities. For the Coleman mental health receivership, the receiver’s office requested $33.9 million from the Mental Health Special Deposit Fund, including $8.2 million for receiver office staffing and $25.3 million to make court-ordered bonus payments permanent. The LAO supported continued oversight but recommended additional steps to address vacancies, including greater out-of-state recruitment, expanded telemental health, and possible consolidation of mental health services. The LAO also recommended reducing the telemental health staffing request and monitoring its effects. Members questioned the long-term cost of receiverships, the pace of compliance, and whether more detailed benchmarks and staffing data should be provided. No formal votes were taken during the portion of the hearing provided.

Transcript Highlights:

• Our pharmaceuticals tend to go up and down.
• We started a pharmaceutical rebate program last year that's looking to save us $10 million this year,
• And, you know, we leverage the DGS contracting, you know, to get better costs for our pharmaceuticals
• then patient-specific claims, like specialty services, ED services, ambulance, hospital, and pharmaceuticals

Keywords: 987, senate, all

Transcript Highlights:

• Our pharmaceuticals tend to go up and down. We do look to generics whenever possible.
• We started a pharmaceutical rebate program last year that's looking to save us $10 million this year,
• And, you know, we leverage the DGS contracting, you know, to get better costs for our pharmaceuticals
• then patient-specific claims, like specialty services, ED services, ambulance, hospital, and pharmaceuticals

Summary: The committee heard an overview from the Office of the Inspector General and California Correctional Health Care Services on prison oversight, medical care, reentry, and related budget requests. The OIG requested $275,000 General Fund for two additional intake analysts, citing a sharp rise in complaints from 3,200 in 2022 to 7,860 in 2025 and explaining that the unit reviews and routes complaints, including PREA and staff misconduct allegations, within 30 days. Its medical inspection unit reported on cycle seven prison health inspections, noting generally adequate case-review performance but weak policy-compliance results, especially in medication management and health care environment indicators, and said it was beginning cycle eight with revised inspection methods. Members questioned the OIG about what kinds of complaints were driving the increase, whether the office tracks validity or systemic patterns, and how it distinguishes duplicative complaints from those already handled by CDCR. OIG said the largest categories were prison conditions and staff misconduct, that it does not determine whether complaints are “valid” in a statistical sense, and that it forwards issues to CDCR or other entities as appropriate. Senators also asked about the medical inspection findings, the remaining prisons not yet delegated back from federal receivership, and whether more detail should be provided in future reports. LAO and Department of Finance staff said they had no concerns with the OIG proposal. The committee then reviewed the correctional health care budget, including staffing, pharmacy, contract medical costs, and the state’s progress toward ending the Plata medical receivership. CDCR said it is trying to reduce vacancies through hiring events, social media outreach, new classifications, and more on-site care, while also using CalAIM to improve reentry services; CalAIM officials reported 89% Medi-Cal activation at release, 87% managed care assignment, 88% reentry care plans, and 59% warm handoffs, with about $14.7 million in reimbursements to date. Members pressed staff on the cost of receivership, the pace of delegation, whether more care could be consolidated into fewer facilities, and whether the state should seek more federal reimbursement or alternative staffing models. Finally, the committee discussed the new mental health receivership and a telemental health staffing proposal. The receiver’s office requested $33.9 million from the Mental Health Special Deposit Fund, including $8.2 million for the receiver’s office and $25.3 million to make court-ordered bonus payments permanent; CDCR also sought about $8.9 million for telemental health staffing, growing to $13 million ongoing. LAO recommended approving the action plan and portions of the telehealth request, but urged the Legislature to monitor progress, consider out-of-state recruitment and expanded telehealth, and avoid across-the-board salary increases; Finance cautioned that out-of-state licensure would require major statutory changes and that staffing-ratio changes would need receiver approval. Senators raised concerns about the high cost of receiverships, vacancy-driven fines, the need for more detailed benchmarks, and whether the state should consolidate mental health populations and better target recruitment to fill hard-to-staff positions.

Transcript Highlights:

• The problem in our pharmaceutical companies was that the cost of non-opiates was so much greater than
• The problem in in in our pharmaceutical<00:10:34.000><c> companies,</c><00:10:34.640><c> the</c><00:10
• :34.880><c> problem</c> pharmaceutical companies, the problem pharmaceutical companies, the problem was

Keywords: 958, all

Summary: The Senate Standing Committee on Health Services met with a quorum and first moved through administrative regulations without comment. The committee then heard Senate Bill 56, sponsored by Senator Gerald Neal, which would require Medicaid and its managed care entities to treat non-opioid pain medications on equal footing with opioid analgesics by prohibiting more restrictive coverage controls, prior authorization, or step therapy for non-opioids. Neal argued the bill would improve access to safer pain treatment options and reduce the risk of opioid use disorder, and Billy O'Brien of Young People in Recovery testified in support, describing personal experiences where non-opioid options were difficult to obtain despite a desire to avoid opioids. After discussion, the bill received a motion and second and passed the committee on a 10-0 vote. The committee then took up Senate Bill 72, sponsored by Senator Don Douglas and presented with Greg Chaffin of Alliance Defending Freedom. Douglas described the bill as a provider recruitment and retention measure intended to protect health care workers from being compelled to act against their conscience and to address workforce shortages and pressure in health care settings. He said the bill would protect individual beliefs while maintaining professionalism. A large number of witnesses then testified, and the chair limited public comments to two minutes each because of the number of speakers and the controversy surrounding the bill. Most public testimony opposed SB 72. Speakers including representatives of the Kentucky Council of Churches, a psychologist, an ordained minister and nurse, a nurse practitioner, and an ACLU policy strategist argued the bill was overly broad, could allow refusals of care by a wide range of health care workers, and could delay or deny treatment, especially for vulnerable patients and in rural or emergency settings. Several cited concerns about discrimination, patient safety, and the lack of adequate protections for patients. One witness recounted the death of an 18-year-old pregnant patient as an example of the harm that can result from delayed care. The transcript ends during additional testimony on SB 72, before any committee vote or final action on that bill is shown.

Transcript Highlights:

• Congress to repeal the 1986 act so that all pharmaceutical companies would be held liable for any harm
• to repeal the 1986 act so<00:47:01.760><c> that</c><00:47:02.079><c> all</c><00:47:02.400><c> pharmaceutical
• </c><00:47:03.119><c> companies</c> so that all pharmaceutical companies so that all pharmaceutical companies

Keywords: 910, house, all

Summary: The committee heard several health-related resolutions and received testimony on each. HCR 28/HR 27 would ask the Department of Health to reconvene a working group on water and air contamination and remediation tied to the Pu‘uloa Range training facility; supporters said nearby residents and the broader public may be exposed to lead and heavy metals, and that further testing and eventual relocation of the range are needed. HCR 35 would request an auditor’s report on the social and financial effects of mandatory insurance coverage for biomarker testing, and HCR 36 would request a similar report on colorectal cancer screening coverage. The Department of Health and cancer advocates supported both, saying biomarker testing helps match patients to the right treatment and that earlier colorectal screening improves outcomes; DOH also cited screening data showing lower screening rates among uninsured people. HCR 134, on limiting cost sharing for diagnostic and supplemental breast imaging, drew support from the Susan G. Komen Foundation and others, who said out-of-pocket costs can delay diagnosis and treatment. HCR 171, on mandatory coverage for continuous glucose monitoring, also drew support from health and disability advocates. HCR 185, on coverage for Native Hawaiian healing and cultural practitioners through federally qualified health centers, received support from Papa Ola Lōkahi and a community testifier who described the value of traditional healing and access gaps. HCR 173, urging DOH outreach and vaccination drives at schools with low vaccination rates, drew support from DOH, DOE, and public health and disability advocates, but also strong opposition from several testifiers who argued the measure was government overreach and raised concerns about vaccine safety and parental choice. Testimony on HCR 173 was the most divided, with supporters emphasizing the need to raise immunization rates to prevent outbreaks and protect vulnerable children, while opponents argued schools should not host vaccine drives and that parents should make vaccination decisions without government involvement. The Department of Health said it is already working with schools and community partners to expand school-based immunization efforts and would prioritize schools with rates under 30%. The State Health Planning and Development Agency also supported the measure, saying rates below 50% are a serious public health concern. No votes or final committee actions were announced in the portion of the meeting provided.

Transcript Highlights:

• I wanted to also note there were questions about pharmaceuticals and spending in the pharmacy space.
• I think what we're learning more about is that pharmaceuticals have a lot to do with it, and then just
• hearing, the administration explained that the declining OSF revenues are due, in part, to the pharmaceutical
• currently in a contract with a company to distribute naloxone through the CalRx program, Amnial Pharmaceuticals

Keywords: 988, house, all

Bills: SB2, SB3, SB5, SB9, SB10, SB14, SB16, SB18, SB34, SB6, SB7, SB8, SB11, SB12, SB13, SB15, SB 2, SB 3, SB 5, SB 9, SB 10, SB 14, SB 16, SB 18, SB 34, SB 6, SB 7, SB 8, SB 11, SB 12, SB 13, SB 15, SB 17, SB 4, SB1, SB2, SB3, SB5, SB9, SB10, SB14, SB16, SB18, SB34, SB6, SB7, SB8, SB11, SB12, SB13, SB15, SB17, SB4

Keywords: flooding, public safety, outdoor warning sirens, disaster preparedness, emergency response, flood warning, outdoor sirens, local government, safety measures, flood management, emergency preparedness, municipal safety, disaster response, disaster relief, emergency funding, Meteorological forecasting, local government assistance, training facilities, hemp regulation, consumable products

Bills: SB2, SB3, SB5, SB9, SB10, SB14, SB16, SB18, SB34, SB6, SB7, SB8, SB11, SB12, SB13, SB15, SB 2, SB 3, SB 5, SB 9, SB 10, SB 14, SB 16, SB 18, SB 34, SB 6, SB 7, SB 8, SB 11, SB 12, SB 13, SB 15, SB 17, SB 4, SB1, SB2, SB3, SB5, SB9, SB10, SB14, SB16, SB18, SB34, SB6, SB7, SB8, SB11, SB12, SB13, SB15, SB17, SB4

Keywords: flooding, public safety, outdoor warning sirens, disaster preparedness, emergency response, flood warning, outdoor sirens, local government, safety measures, flood management, emergency preparedness, municipal safety, disaster response, disaster relief, emergency funding, Meteorological forecasting, local government assistance, training facilities, hemp regulation, consumable products